eMC Medicine Guides  
The electronic Medicines Compendium (eMC) contains information about UK licensed medicines.
go to eMC homepage
Search for:  
  Advanced Search

Meda Pharmaceuticals

Sky Way House, Parsonage Road, Takeley, Bishop's Stortford, CM22 6PU
Telephone: 0845 460 0000
Fax: 0845 460 0002
Medical Information Direct Line: +44 (0)1748 828 810
Medical Information e-mail: meda@professionalinformation.co.uk
Medical Information Fax: +44 (0)1748 828 801
Out of Hours contact: +44 (0)1748 828 810

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?
Summary of Product Characteristics last updated on the eMC: 23/12/2010
SPC Ancotil 2.5g/250ml Solution for Infusion

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 23/12/2010 and displayed until Current
Reasons for adding or updating:
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   01-Dec-2010
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company
Amendments to sections 4.3., 4.4., 4.5. and 10 of the SPC
Updated on 13/10/2010 and displayed until 23/12/2010
Reasons for adding or updating:
  • Change to section 6. 4 - Special Precautions for Storage
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   01-Aug-2010
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company
Change to section 6.4 - deletion of the recommdation that if precipitation of Ancotil occurs, redissolve by heating to 80 deg C for not more than 30 minutes.
Updated on 12/10/2010 and displayed until 13/10/2010
Reasons for adding or updating:
  • Change to section 4.2 - Posology and method of administration
Date of revision of text on the SPC:   07-Oct-2010
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company
Update to section 4.2
Updated on 06/08/2009 and displayed until 12/10/2010
Reasons for adding or updating:
  • Change to section 7 - Marketing Authorisation Holder
  • Change to section 9 - Date of first Authorisation/renewal of the Authorisation
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   01-Jun-2009
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company
Change to Section 7. MAH,   Section 9. Date of First Authorisation/Renewal of Authorisation,  Section 10.Date of Revision of Text
Updated on 12/07/2007 and displayed until 06/08/2009
Reasons for adding or updating:
  • Correction of spelling/typing errors
Updated on 01/08/2005 and displayed until 12/07/2007
Reasons for adding or updating:
  • Change to section 1 - trade name
Updated on 20/07/2004 and displayed until 01/08/2005
Reasons for adding or updating:
  • Change to section 7 - Marketing Authorisation Holder
Updated on 20/07/2004 and displayed until 20/07/2004
Reasons for adding or updating:
  • Change to section 7 - Marketing Authorisation Holder
Updated on 19/09/2003 and displayed until 20/07/2004
Reasons for adding or updating:
  • Change to section 4.1 - Therapeutic Indications
Updated on 07/08/2001 and displayed until 19/09/2003
Reasons for adding or updating:
  • Change to section 1 - trade name

Active Ingredients/Generics

 
  flucytosine